Gastrointestinal Stromal Tumor, Malignant Melanoma, Renal Cell Carcinoma | Access and Reimbursement | EU5 | 2016
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and prescribers. In our analysis, we assess the influence of trial design on treatment and reimbursement decisions regarding current and emerging therapies for malignant melanoma, renal cell carcinoma (RCC), and gastrointestinal stromal tumors (GIST). In addition, we explore payers’ and prescribers’ cost-sensitivity and preference for trial design features, such as primary end points and comparators.
Related Market Assessment Reports
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete as a result of opioid medications. The treatment of OIC relies on various prescription…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
